HC Wainwright Raises Replimune Group (NASDAQ:REPL) Price Target to $51.00

Replimune Group (NASDAQ:REPL – Get Rating) had its price target raised by HC Wainwright from $50.00 to $51.00 in a research report released on Monday, The Fly reports. HC Wainwright also issued estimates for Replimune Group’s Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.84) EPS, Q3 2024 earnings at ($0.88) EPS, Q4 […]

Related Keywords

Philip Astley Sparke ,Colin Love ,Jeanm Franchi ,Piper Sandler ,Panagora Asset Management Inc ,Replimune Group Price Performance ,Ameritas Investment Partners Inc ,News Ratings For Replimune Group Daily ,Replimune Group Inc ,Group Plc ,Securities Exchange Commission ,Institutional Investors Weigh In On Replimune Group ,Analyst Recommendations For Replimune Group ,Life Insurance Co ,Replimune Group ,Get Rating ,Exchange Commission ,General Group Plc ,Investment Partners ,Asset Management ,Robert Coffin ,Replimune Group Daily ,Nasdaq Repl ,Trepl ,Medical ,Boost Price Target ,Hc Wainwright ,